Asco 2019 event analyser – low-key meeting belies some huge stock moves
Moderna’s Not the Only One: A Look at the mRNA Market
A Record Year: A Look at the Biotech IPOs for Q4 2018
Biopharma in 2019
Science Top Company List Ranks Innovation and Work Culture
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four or five years ago that early work in immuno-oncology was going to have a huge effect, and it did, when in 2017 the U.S. Food and Drug … Συνεχίστε να διαβάζετε Taking a Look at Trends in Biotherapeutics.
Oncorus, a biotechnology company based in Cambridge, Massachusetts, announced that Theodore (Ted) T. Ashburn had been chosen as the company’s new president and chief executive officer. He will also serve on the company’s board of directors. Ashburn was most recently the head of Oncology Development for Moderna Therapeutics. Moderna focuses on developing vaccines and therapeutics based on messenger RNA. The Boston Business Journal notes that … Συνεχίστε να διαβάζετε Moderna Executive Heads to Oncorus as New President/CEO.
The last time GEN published a list of top-10 private financings of early-stage biopharmas and developers of diagnostic or therapeutic technologies back in 2016, the top company turned heads by raising a then-staggering $474 million, while the No. 10 company garnered $110 million. Two years later, the same number-one company is still on top among young companies in … Συνεχίστε να διαβάζετε Top 10 Young Companies in the Money, January–June 2018.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period. A recent analysis indicated there were nine biotech IPOs by … Συνεχίστε να διαβάζετε A Deep Dive into This Year’s Biotech IPOs.
Despite market volatility, ongoing debates about drug pricing, and various scandals such as the Theranos debacle, everything Martin Shkreli touches, and Novartis paying President Trump’s attorney Michael Cohen $1.2 million for access to the president, it hasn’t slowed down biotech startups or investors. To the contrary, so far it’s been a big year for biopharma investment. It’s been a pretty good year for mergers and acquisitions … Συνεχίστε να διαβάζετε 2018 Is a Hot Year for Biotech Startups, IPOs and M&A Activity.